You are here

Valeant leads the way in steep price increase of skin drugs

New York

TWO drugs sold by Valeant Pharmaceuticals International to treat cancer-related skin conditions increased in price by about 1,700 per cent over the last six years, according to a newly published survey that found big increases in the cost of dermatology drugs across the board.

sentifi.com

Market voices on:

Powered by GET.comGetCom